Want to see FR:VETO full AI Analyst Report?
Top Page
VETOQUINOL
(VETO)
Select Model
Select Model
Rating:72Outperform
Price Target:
€86.00
▲(19.78% Upside)
Action:Reiterated
Date:09/12/26
The score is primarily supported by strong financial quality—especially the very low leverage and generally resilient profitability. Offsetting this are weaker near-term technicals (deeply oversold readings with negative MACD) and fundamental watch items including soft revenue momentum and uneven cash conversion/FCF. Valuation is reasonable (mid-teens P/E with a modest yield), but not compelling enough to fully counter the current technical and cash-flow concerns.
Positive Factors
Conservative balance sheet
Minimal leverage materially reduces refinancing and solvency risk, giving Vetoquinol greater resilience during weaker trading conditions. Rising equity and assets also preserve flexibility to fund research, product development, operations, and shareholder distributions without relying heavily on external debt.
Negative Factors
Weak revenue momentum
A recent top-line decline suggests that growth and market expansion are currently limited, which can constrain operating leverage and reduce the resources available for product investment. If this softness persists, it may offset the benefit of otherwise resilient margins and financial quality.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal leverage materially reduces refinancing and solvency risk, giving Vetoquinol greater resilience during weaker trading conditions. Rising equity and assets also preserve flexibility to fund research, product development, operations, and shareholder distributions without relying heavily on external debt.
Read all positive factors
VETOQUINOL (VETO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.01B
Dividend Yield1.09%
Average Volume (3M)7.00K
Price to Earnings (P/E)16.0
Beta (1Y)0.39
Revenue Growth-0.95%
EPS Growth6.39%
CountryFR
Employees2,526
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.32
Shares Outstanding11,881,902
10 Day Avg. Volume7,887
30 Day Avg. Volume6,999
Financial Highlights & Ratios
PEG Ratio-21.04
Price to Book (P/B)1.68
Price to Sales (P/S)1.89
P/FCF Ratio19.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.43
Revenue Forecast (FY)€526.81M
VETOQUINOL Business Overview & Revenue Model
Company Description
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Am...
How the Company Makes Money
Vetoquinol makes money primarily by selling animal health products (veterinary medicines and related health products) to veterinary wholesalers/distributors, veterinary clinics, and other animal-health channel partners, with revenues recognized fr...
VETOQUINOL Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 527.37M | 525.70M | 539.20M | 529.27M | 539.78M | 521.27M |
| Gross Profit | 170.68M | 160.36M | 387.45M | 291.38M | 172.37M | 167.37M |
| EBITDA | 350.60M | 348.93M | 114.08M | 112.33M | 103.46M | 116.86M |
| Net Income | 62.73M | 57.30M | 58.69M | 55.56M | 47.99M | 62.86M |
Balance Sheet | ||||||
| Total Assets | 770.57M | 763.63M | 744.13M | 692.23M | 651.85M | 624.56M |
| Cash, Cash Equivalents and Short-Term Investments | 235.20M | 221.08M | 206.33M | 147.46M | 93.71M | 69.00M |
| Total Debt | 12.35M | 15.29M | 21.12M | 17.63M | 17.42M | 15.38M |
| Total Liabilities | 161.77M | 172.19M | 168.20M | 165.12M | 167.19M | 183.21M |
| Stockholders Equity | 608.73M | 591.37M | 575.84M | 527.01M | 484.57M | 441.26M |
Cash Flow | ||||||
| Free Cash Flow | 87.08M | 51.35M | 68.15M | 70.38M | 39.90M | 56.76M |
| Operating Cash Flow | 101.77M | 72.08M | 85.83M | 89.39M | 62.39M | 89.17M |
| Investing Cash Flow | -18.39M | -20.56M | -15.65M | -18.88M | -21.52M | -33.45M |
| Financing Cash Flow | -26.98M | -25.08M | -16.03M | -15.50M | -16.06M | -120.31M |
VETOQUINOL Technical Analysis
Positive
71.80
Price Trends
74.76
Positive
73.09
Positive
75.64
Positive
Market Momentum
2.22
Negative
74.54
Negative
69.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VETO, the sentiment is Positive. The current price of 71.8 is below the 20-day moving average (MA) of 78.22, below the 50-day MA of 74.76, and below the 200-day MA of 75.64, indicating a bullish trend. The MACD of 2.22 indicates Negative momentum. The RSI at 74.54 is Negative, neither overbought nor oversold. The STOCH value of 69.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VETO.
VETOQUINOL Peers Comparison
UnderperformOutperform
Sector (55)
FR:VETO
VETOQUINOL
85.00
11.41
15.50%
FR:VIRP
Virbac SA
347.00
-5.94
-1.68%
VETOQUINOL Corporate Events
Vetoquinol Delivers H1 2026 Profitability Boost and Strengthens Cash for Future Growth
Sep 10, 2026
Vetoquinol reported a return to growth in the first half of fiscal 2026, with sales rising 3.4% at constant exchange rates to €259.3 million, driven by its Essentials segment and strong 13.1% growth in the U.S. market. Essentials products, n...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.